PharmaEssentia
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel chec… Read more
PharmaEssentia (6446) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.075x
Based on the latest financial reports, PharmaEssentia (6446) has a cash flow conversion efficiency ratio of 0.075x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$2.23 Billion) by net assets (NT$29.75 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PharmaEssentia - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how PharmaEssentia's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
PharmaEssentia Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PharmaEssentia ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Spirax-Sarco Engineering plc
PINK:SPXSF
|
0.147x |
|
Sinomine Resource Exploration Co Ltd
SHE:002738
|
0.070x |
|
Eagle Materials Inc
NYSE:EXP
|
0.343x |
|
Direct Line Insurance Group PLC
PINK:DIISY
|
-0.091x |
|
Compagnie Générale des Établissements Michelin Société en commandite par actions
PINK:MGDDF
|
0.022x |
|
Airports Of Thailand PCL
BK:AOT
|
0.071x |
|
Paramount Skydance Corporation Class B Common Stock
NASDAQ:PSKY
|
0.007x |
|
Turkish Airlines
IS:THYAO
|
0.036x |
Annual Cash Flow Conversion Efficiency for PharmaEssentia (2010–2024)
The table below shows the annual cash flow conversion efficiency of PharmaEssentia from 2010 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | NT$27.47 Billion | NT$2.55 Billion | 0.093x | +414.71% |
| 2023-09-30 | NT$23.95 Billion | NT$-705.56 Million | -0.029x | +76.24% |
| 2022-09-30 | NT$12.14 Billion | NT$-1.51 Billion | -0.124x | +78.59% |
| 2021-09-30 | NT$4.25 Billion | NT$-2.46 Billion | -0.579x | -56.02% |
| 2020-09-30 | NT$3.92 Billion | NT$-1.46 Billion | -0.371x | +11.40% |
| 2019-09-30 | NT$2.26 Billion | NT$-945.02 Million | -0.419x | -25.28% |
| 2018-09-30 | NT$2.47 Billion | NT$-826.84 Million | -0.334x | -46.30% |
| 2017-09-30 | NT$3.46 Billion | NT$-790.48 Million | -0.229x | -48.57% |
| 2016-09-30 | NT$4.27 Billion | NT$-657.17 Million | -0.154x | +79.86% |
| 2015-09-30 | NT$689.56 Million | NT$-526.91 Million | -0.764x | -87.29% |
| 2014-09-30 | NT$1.47 Billion | NT$-599.15 Million | -0.408x | -204.68% |
| 2013-09-30 | NT$2.13 Billion | NT$-285.17 Million | -0.134x | +61.98% |
| 2012-09-30 | NT$549.52 Million | NT$-193.56 Million | -0.352x | +91.20% |
| 2011-09-30 | NT$41.34 Million | NT$-165.45 Million | -4.002x | -1195.82% |
| 2010-09-30 | NT$244.19 Million | NT$-75.42 Million | -0.309x | -- |